Meeting
2014 ASCO Annual Meeting
Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials.
Authors
Olivia Pagani
Institute of Oncology of Southern Switzerland, SAKK & IBCSG, Lugano Viganello, Switzerland
Olivia Pagani , Meredith M. Regan , Barbara Walley , Gini F. Fleming , Marco Colleoni , Istvan Lang , Henry Leonidas Gomez , Carlo Tondini , Harold J. Burstein , Edith A. Perez , Eva Ciruelos , Vered Stearns , Herve R. Bonnefoi , Silvana Martino , Charles E. Geyer Jr., Manuela Rabaglio-Poretti , Alan S. Coates , Richard D. Gelber , Aron Goldhirsch , Prudence A. Francis
Organizations
Institute of Oncology of Southern Switzerland, SAKK & IBCSG, Lugano Viganello, Switzerland, IBCSG Statistical Center, Dana-Farber Cancer Institute, Boston, MA, NCIC Clinical Trials Group, Kingston, ON, Canada, The University of Chicago Medical Center & Alliance, Chicago, IL, European Institute of Oncology & IBCSG, Milan, Italy, National Institute of Oncology, Budapest, Hungary, Instituto Nacional de Enfermedades Neoplásicas & IBCSG, Lima, Peru, Osp. Papa Giovanni XXIII, Bergamo, Italy, Dana-Farber Cancer Institute & Alliance, Boston, MA, Mayo Clinic & Alliance, Jacksonville, FL, University Hospital 12 de Octubre, Madrid, Spain, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and ECOG, Baltimore, MD, Bergonié Institute & EORTC, Bordeaux, France, The Angeles Clinic and Research Institute & SWOG, Santa Monica, CA, Massey Cancer Center, Virginia Commonwealth University School of Medicine & NRG Oncology, Richmond, VA, Institute of Medical Oncology & International Breast Cancer Study Group, Berne, Switzerland, International Breast Cancer Study Group, Berne, Switzerland, Peter MacCallum Cancer Center, ANZBCTG, Melbourne, Australia
Research Funding
Other
Background: Adjuvant endocrine therapy with AI vs T improves outcomes in postmenopausal HR+ BC. TEXT and SOFT were designed to test whether adjuvant AI improves outcomes in premenopausal women with HR+ BC treated with OFS (AI question) and to determine the value of OFS in women who remain premenopausal and are suitable for adjuvant T (OFS question). Methods: TEXT and SOFT, randomized phase 3 trials, enrolled 5,738 premenopausal women with HR+ early BC from Nov03 to Apr11 (2672 TEXT; 3066 SOFT). TEXT randomized women within 12wk of surgery to 5y E+OFS vs T+OFS; chemotherapy (CT) was optional and concurrent with OFS. SOFT randomized women to 5y E+OFS vs T+OFS vs T alone, either within 12wk of surgery if no CT planned, or within 8mo of completing (neo)adjuvant CT. OFS was by choice of 5y triptorelin, oophorectomy, or ovarian irradiation. The primary endpoint is disease-free survival (DFS: randomization until invasive local, regional, distant recurrence, or contralateral breast; 2nd malignancy; death). Due to low event rates, protocol amendments in 2011 changed the analysis plans to answer the AI question (E+OFS vs T+OFS) by joint analysis of TEXT and SOFT. By Q3’2013 with >5y median follow-up, 436 DFS events were projected, providing 84% power for HR=0.75 with E+OFS vs T+OFS (stratified logrank 2-sided α=0.05). Results: At 5.7y median follow-up, 514 (11%) DFS events were reported in the ITT population comparing E+OFS (n=2346) vs T+OFS (n=2344). Patients assigned E+OFS had significantly reduced DFS hazard (HR=0.72; 95% CI, 0.60-0.86; P=0.0002) vs T+OFS; 5y DFS was 91.1% vs 87.3%. Reductions were similar for secondary endpoints of BC-free interval (HR=0.66 (0.55-0.80) 5y BCFI 92.8% vs 88.8%) and distant recurrence-free interval (HR=0.78 (0.62-0.97)), though not overall survival (HR=1.14 (0.86-1.51)) at this early follow-up (194 (4%) deaths). Grade 3-4 targeted AEs were reported in 31% E+OFS vs 29% T+OFS patients. Conclusion: In premenopausal women with HR+ BC, adjuvant treatment with E+OFS significantly reduced the risk of recurrence compared to T+OFS. Clinical trial information: NCT00066703/NCT00066690
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Details
Session Type
Plenary Session
Session Title
Plenary Session Including the Science of Oncology Award and Lecture
Track
Special Sessions,Core Sessions
Sub Track
ER+
Clinical Trial Registration Number
NCT00066703/NCT00066690
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr LBA1)
DOI
10.1200/jco.2014.32.18_suppl.lba1
Abstract #
LBA1
Abstract Disclosures
Similar Abstracts
Abstract
2022 ASCO Annual Meeting
Estradiol (E2) levels in premenopausal women with hormone receptor-positive (HR+) breast cancer (BC) on ovarian function suppression (OFS) with gonadotropin-releasing hormone agonists (GnRHa).
First Author: Megan Elizabeth Tesch
Abstract
2023 ASCO Annual Meeting
Real-world outcomes with adjuvant nonsteroidal aromatase inhibitors (NSAIs) vs tamoxifen (TAM) in patients with hormone receptor−positive/human epidermal growth factor receptor 2−negative (HR+/HER2−) early breast cancer (EBC): A US database analysis.
First Author: Stephanie L. Graff
Abstract
2022 ASCO Annual Meeting
Adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: 8-year follow-up of the randomized ASTRRA trial.
First Author: Soo Yeon Baek
Abstract
2023 ASCO Annual Meeting
A randomized phase 2 non-inferiority trial of (Z)-endoxifen and exemestane + goserelin as neoadjuvant treatment for premenopausal women with ER+/HER2- breast cancer (EVANGELINE).
First Author: Matthew P. Goetz